The British Journal of Cardiology

This site is intended for UK healthcare professionals

 
BJC_tv_logo_white
Sign in

Featured Videos #1

“Treatment Limbo” – what is it and how can we avoid it?

Sponsored

Dr Adie Viljoen and Dr Mohamed Elnaggar address the challenge of “Treatment Limbo”, in dyslipidaemia management, where patients fail to achieve low-density lipoprotein cholesterol (LDL-C) targets yet remain ineligible for advanced therapies. They introduce a guideline-aligned, alternative approach that tailors treatment to baseline LDL-C and distance to goal, supporting timely intervention and helping to reduce the risk of recurrent cardiovascular events.

Click here to access prescribing information and adverse event reporting information for Praluent® (alirocumab).

MAT-XU-2504094 (v1.0) | November 2025

Amyloidosis overview – prevalence, pathophysiology and treatment approaches

Amyloidosis overview – prevalence, pathophysiology and treatment approaches

This Masterclass was developed in collaboration with the National Amyloidosis Centre, London UK

Amyloidosis is rapidly gaining recognition as a previously under-diagnosed cause of cardiomyopathy and heart failure. Here, experts from the National Amyloidosis Centre – the only centre in the UK specialising in the management of the condition – provide an overview of its prevalence, symptoms and key treatment principles.
Referral and diagnosis of suspected cardiac amyloidosis

Referral and diagnosis of suspected cardiac amyloidosis

This Masterclass was developed in collaboration with the National Amyloidosis Centre, London UK

Assessment of a patient with suspected amyloidosis requires a careful diagnostic workup, including cardiac imaging to identify amyloid infiltration in heart tissue that could lead to diastolic dysfunction and heart failure. In this Masterclass, clinicians and scientists from the National Amyloidosis Centre describe the laboratory tests and imaging techniques used to make an accurate diagnosis.
Amyloidosis signs and symptoms – red flags for cardiologists

Signs and symptoms of amyloidosis – red flags for cardiologists

This Masterclass was developed in collaboration with the National Amyloidosis Centre, London UK

Effective treatment of cardiac amyloidosis is dependent on early diagnosis; it is therefore important that clinicians have a high index of suspicion for the condition in their patients. Dr Josephine Mansell from the National Amyloidosis Centre outlines the “red flag” signs and symptoms that cardiologists, nurses or other healthcare professionals may observe in their patients, and which should prompt consideration of referral for a full diagnostic workup.

Digital transformations in cardiovascular medicine – where do we begin?

Dr Sarah Hudson and Charles Lowe discuss the latest advancements in digital innovation both supporting and challenging cardiology clinicians in the UK. Topol Fellow, Dr Hudson shares her wealth of knowledge and experience as a cardiologist with Charles Lowe, who’s worked in the digital healthcare space for over 25 years. In this fascinating conversation, we discover what is happening in cardiology clinics and what the future might hold for cardiologists. Look out for future videos covering these topics in more detail:

Urgent reversal of anticoagulants – lessons for practice

In recent years, there has been a switch to direct oral anticoagulants (DOACs) as first-line thrombosis prevention, with fewer people started on a vitamin K antagonist, such as warfarin. This has led to an increase in number of people taking anticoagulants and, therefore, an increased risk of intracranial and intracerebral haemorrhages and gastrointestinal bleeds. Listen to Richard Buka, Clinical Research Fellow Institute of Cardiovascular Sciences at the University of Birmingham, discuss the challenges clinical teams face in the reversal of these drugs. He explores the findings of recent trials of Andexanet alfa and considers how effective these drugs really are and what it means in practice.

© 2025 Medinews Cardiology Ltd, a wholly-owned subsidiary of OmniaMed Communications Ltd   |   Privacy & cookies policy   |   Terms & conditions

 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.